Last edition
News about "PTSD treatment"
Silo Pharma Signs LOI with Allucent for Phase I Development of SPC-15
Silo Pharma has executed a Letter of Intent (LoI) with Allucent to support the phase I clinical development of SPC-15, with planned single-ascending dose and multiple-ascending dose studies representing a key clinical milestone for its intranasal treatment targeting PTSD and anxiety disorders.
PTSD Treatment | 31/12/2025 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members